Corporate presentation will be held on
Wednesday, December 4, 2024, at
1:00 p.m. ET
NEW
HAVEN, Conn., Nov. 21,
2024 /PRNewswire/ -- Trevi Therapeutics,
Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of patients with chronic cough in
idiopathic pulmonary fibrosis (IPF) and refractory chronic cough
(RCC), today announced that Jennifer
Good, President and Chief Executive Officer, will be
presenting at the Piper Sandler 36th Annual Healthcare
Conference on Wednesday, December 4,
at 1:00p.m. ET. Held from
December 3-5 in New York, Ms. Good and Ms. Delfini, Chief
Financial Officer, will also participate in investor meetings with
attendees at the event. The presentation and meetings will be
available for in-person attendees.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine extended-release) for the treatment of chronic cough in
patients with idiopathic pulmonary fibrosis (IPF) and refractory
chronic cough (RCC). Haduvio acts on the cough reflex arc both
centrally and peripherally as a kappa agonist and a mu antagonist
(KAMA), which are opioid receptors that play a key role in
controlling cough hypersensitivity. Nalbuphine is not currently
scheduled by the U.S. Drug Enforcement Agency.
Chronic cough is highly prevalent among approximately 140,000
IPF patients in the U.S., with up to 85% of IPF patients
experiencing chronic cough. The impact of chronic cough is
significant with some IPF patients coughing up to 1,500 times per
day and may lead to worsening disease, a higher risk of
progression, death, or need for lung transplant. Chronic cough also
often leads to a decline in patients' social, physical, and
psychological quality of life. There are no approved therapies for
the treatment of chronic cough in IPF and current off-label
treatment options provide minimal benefit to patients.
Refractory chronic cough affects approximately 2-3 million
adults in the U.S. and is caused by cough reflex hypersensitivity
in both the central and peripheral nerves. It is highly disruptive
and accompanied by a wide range of complications, ranging from
urinary incontinence in females to sleep disruption and social
embarrassment that causes significant social and economic burdens
for patients and those around them. Haduvio is being developed for
the treatment of moderate to severe RCC. There are also no approved
therapies for RCC in the U.S.
Trevi intends to propose Haduvio as the trade name for oral
nalbuphine ER. Its safety and efficacy have not been evaluated by
any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie Barrett
Trevi Therapeutics,
Inc.
203-304-2499
k.barrett@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-piper-sandler-36th-annual-healthcare-conference-302312050.html
SOURCE Trevi Therapeutics, Inc.